Skip to main content
OpenTrials
Completed

NCT Number: NCT03059862

The Role of Dietary Tryptophan on Aryl Hydrocarbon Receptor Activation

This study evaluates the role of dietary L-tryptophan, an essential amino acid, in the activation of a specific cellular component: the aryl hydrocarbon receptor.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

McMaster Health Sciences Centre

Hamilton, Ontario, L8N3Z5, Canada

About this study

The Aryl hydrocarbon receptor (AHR) is a ligand-dependent transcription factor implicated in a range of key cellular events. In the gut, AHR is crucial for maintaining intestinal barrier immune homeostasis. The physiology of the AHR, however, is not completely understood; its precise gut luminal activators and functional consequences are unknown.

Some AHR ligands originate from the diet. Commensals play crucial roles in metabolizing tryptophan and other amino acids such as tyrosine, with the subsequent production of tryptophan metabolites. Previous studies show that inflammatory bowel disease (IBD) patients have impaired production of AHR agonists by the microbiota. Furthermore, dietary supplementation with tryptophan ameliorates clinical parameters of colitis in rodent models. Whether these findings translate into human pathophysiology has not been explored.

In the present study, the investigators will evaluate the effect of high- versus low-tryptophan diet on AHR activation in healthy participants. Briefly, participants will be instructed to follow a standardized low-tryptophan diet and will be randomized to a 3-week L-tryptophan supplement or placebo. Later, after a 2-week washout period, participants will crossover to the other arm. In addition, the effect of tryptophan and microbiota-derived metabolites on AHR activation will be analyzed.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy volunteer between 18 and 75 years of age.

Exclusion criteria

  • Rome IV criteria for any functional gastrointestinal disorder.

Treatment and study plan

L-tryptophan

Dietary Supplement

3 g/day of L-tryptophan added to the standardized low-tryptophan diet. Duration: 3 weeks.

Placebo

Dietary Supplement

A placebo will be added to the standardized low-tryptophan diet. Duration: 3 weeks.

Primary outcomes

  1. AHR activation levels in stool and duodenal content.

    Time frame: three weeks

    Changes in AHR activation levels will be assessed in stool and duodenal samples before and after the intervention (high- and low-tryptophan diets) using an AHR cell-reporter line.

Secondary outcomes

  1. Bacterial and fungal microbiota composition in stool, duodenum and rectum/sigmoid biopsies.

    Time frame: Three weeks

    Changes in bacterial and fungal microbiota composition will be assessed before and after the intervention in stool samples, duodenum and rectum biopsies.

  2. Tryptophan metabolites levels, including host and bacterial catabolites, in blood, urine and stool.

    Time frame: Three weeks

    Changes in tryptophan metabolites leves will be compared before and after the intervention, in blood, urine and stool samples.

  3. mRNA levels in duodenal and rectum/sigmoid biopsies.

    Time frame: three weeks

    Changes in mRNA levels in duodenal and rectum/sigmoid biopsies will be assessed before and after the intervention.

  4. Cytokines in serum.

    Time frame: three weeks.

    Changes in cytokines in the serum (IL-22, IL-6, IL-2, IL-10, IL-12p70, IL-23p19, IFNγ, TNFα and CRP will be measured by ELISA in cell culture supernatants after stimulation with LPS, curdlan and ConA ) will be measured before and after the intervention and patients will be grouped into two categories for each measurement: high vs. low, according to the cutoff reference test value for each of the cytokines.

  5. Gastrointestinal symptoms

    Time frame: three weeks.

    Changes in gastrointestinal symptoms before and after the intervention will be assessed using a validated questionnaire (The Gastrointestinal Symptoms Rating Scale)

  6. Mood

    Time frame: three weeks

    Changes in mood before and after the intervention will be assessed using a validated questionnaire (Hospital anxiety and depression scale)

Sponsors and collaborators

Lead sponsor

McMaster University

Other

Collaborators

  • Canadian Institutes of Health Research (CIHR)
  • National Research Agency, France

Registry information

Official study title

The Role of Tryptophan on Aryl Hydrocarbon Receptor Activation: a Randomized, Double Blind, Placebo-controlled, Crossover Design Pilot Trial

Acronym: Aryl-IMMUNE

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Feb 23, 2017
Registry last updated
Apr 13, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.